Results 1 to 10 of about 25,935 (265)

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Frontiers in Oncology, 2020
Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in normal tissues, making most subtypes unsuitable as targets for cancer therapy. However, the disialoganglioside GD2 subtype has limited expression in normal tissues but is
Bassel Nazha
exaly   +3 more sources

Predicting GD2 expression across cancer types by the integration of pathway topology and transcriptome data [PDF]

Frontiers in Bioinformatics
BackgroundThe disialoganglioside GD2 is a key cancer therapy target due to its overexpression in several cancers and limited presence in normal tissues. However, experimental assessment is technically challenging and not routinely available. We developed
Arsenij Ustjanzew, Arsenij Ustjanzew, Arsenij Ustjanzew, Federico Marini, Federico Marini, Federico Marini, Saskia Wagner, Arthur Wingerter, Roger Sandhoff, Jörg Faber, Jörg Faber, Jörg Faber, Claudia Paret, Claudia Paret, Claudia Paret, Claudia Paret, Claudia Paret   +16 more
doaj   +2 more sources

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients

Journal of Hematology and Oncology, 2018
Background Chimeric antigen receptor (CAR)-engineered T cells have demonstrated promising clinical efficacy in patients with B cell lymphoma. However, the application of CAR-T cell therapy in the treatment of other solid tumors has been limited.
Zhihong Chi, Xinan Sheng, Lu Si
exaly   +3 more sources

Harnessing a bispecific αGD2 × αCD3 protein engager to target GD2-overexpressing lung tumors [PDF]

Scientific Reports
Lung cancer remains one of the most prevalent and lethal malignancies worldwide, with persistently poor 5-year survival rates across all stages. The development of novel therapies is therefore crucial for overcoming treatment resistance, improving ...
Nunghathai Sawasdee, Aussara Panya, Jatuporn Sujjitjoon, Pa-thai Yenchitsomanus, Chutamas Thepmalee   +4 more
doaj   +2 more sources

Ganglioside GD2 is a potential candidate marker for lung cancer stem cells [PDF]

Jichu yixue yu linchuang, 2023
Objective To explore the feasibility of ganglioside GD2 as a marker for lung cancer stem cells (LCSCs). Methods Cancer stem cells (CSCs) of lung cancer cell lines were enriched by spheroid culturing in vitro; The expression of stemness-related genes ...
LI Zhen, DUAN Zhaojun, LUO Yunping
doaj   +1 more source

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas

Frontiers in Immunology, 2023
BackgroundDiffuse intrinsic pontine gliomas (DIPGs) are rare and fatal pediatric brainstem gliomas with no cure. Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells have been proven effective in treating glioblastoma (GBM) in preclinical
Pengcheng Zuo, Yaopeng Li, Chi He, Tantan Wang, Xu Zheng, Hao Liu, Zhen Wu, Junting Zhang, Xuebin Liao, Xuebin Liao, Liwei Zhang, Liwei Zhang   +11 more
doaj   +1 more source

A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics

Molecular Therapy: Nucleic Acids, 2021
Because current mainstream anti-glycolipid GD2 therapeutics for neuroblastoma (NB) have limitations, such as severe adverse effects, improved therapeutics are needed. In this study, we developed a GD2 aptamer (DB99) and constructed a GD2-aptamer-mediated
Liyu Zhang, Meng Wang, Zeen Zhu, Shengquan Chen, Haibin Wu, Ying Yang, Fengyu Che, Qiao Li, Hui Li   +8 more
doaj   +1 more source

GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells

OncoImmunology, 2020
Expression of the disialoganglioside GD2 has been identified as a marker antigen associated with a breast cancer stem-like cell (BCSC) phenotype. Here, we report on the evaluation of GD2 as a BCSC-specific target antigen for immunotherapy. GD2 expression
Christian M. Seitz, Sarah Schroeder, Philipp Knopf, Ann-Christin Krahl, Jana Hau, Sabine Schleicher, Manuela Martella, Leticia Quintanilla-Martinez, Manfred Kneilling, Bernd Pichler, Peter Lang, Daniel Atar, Karin Schilbach, Rupert Handgretinger, Patrick Schlegel   +14 more
doaj   +1 more source

A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigs. [PDF]

PLoS ONE, 2014
We recently constructed a novel non-replicating dominant-negative HSV-2 recombinant viral vaccine (CJ2-gD2) capable of expressing various HSV-2 antigens that are dominant targets of HSV-2-specific CD8 T-cell response.
Pengwei Zhang, Lining Xie, John W Balliet, Danilo R Casimiro, Feng Yao   +4 more
doaj   +1 more source

Surface expression of the immunotherapeutic target GD2 in osteosarcoma depends on cell confluency

Cancer Reports, 2021
Background Chimeric antigen receptor (CAR) T‐cell therapy of pediatric sarcomas is challenged by the paucity of targetable cell surface antigens. A candidate target in osteosarcoma (OS) is the ganglioside GD2, but heterogeneous expression of GD2 limits ...
Malena Wiebel, Sareetha Kailayangiri, Bianca Altvater, Jutta Meltzer, Kay Grobe, Sabine Kupich, Claudia Rossig   +6 more
doaj   +1 more source